enoblituzumab

Ligand id: 9589

Name: enoblituzumab

References
1. Johnson LS, Huang L, Moore PA, Loo DT, Chen FZ. (2014)
Antibodies reactive with B7-H3 and uses thereof.
Patent number: US8802091. Assignee: Macrogenics, Inc.. Priority date: 04/05/2010. Publication date: 12/08/2014.
2. Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y et al.. (2012)
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Clin. Cancer Res., 18 (14): 3834-45. [PMID:22615450]